1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Distribution
McKesson Corporation

McKesson Corporation

MCK
McKesson CorporationUS flagNew York Stock Exchange
840.90
USD
+16.41
- -
98.45BMarket Cap
McKesson Corporation
MCK
(New York Stock Exchange)

Recent

price

840.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
434.43
497.24
519.98
599.97
771.75
829.93
898.34
1,001.72
1,093.46
1,276.52
1,483.36
1,733.2
1,961.1
2,319.45
2,818.3
3,264
3,265.32
Revenue per Share
4.66
5.7
5.69
5.52
6.36
9.82
22.94
0.32
0.17
4.97
-28.26
7.31
25.23
22.54
25.86
38.53
38.54
Basic EPS, GAAP
7.56
10.37
8.86
11.86
11.06
13.02
18.92
18.1
17.75
21.37
24.29
26.57
33.8
29.15
43.55
46.27
46.29
Free Cash Flow per Basic Share
0.66
0.79
0.83
0.93
0.98
1.06
1.14
1.26
1.49
1.62
1.72
1.82
2.07
2.36
2.71
3.08
3.08
Dividend per Share
31.99
38.43
44.28
50.03
54.78
36.36
59.69
62.45
63.33
71.96
51.08
59.3
87.16
112.47
140.69
180.37
180.45
Book Value per Share
4.84
0.2
-6.83
-19.56
-16.32
-10.4
-7.47
-16.88
-17.18
-32.07
-68.03
-87.34
-97.19
-103.91
-103.45
-131.3
-131.36
Tangible Book Value per Share
258
246
235
229
232
230
221
208
196
181
161
152
141
133
127
124
124
Basic Weighted Avg Shares
112,084
122,321
122,196
137,392
179,045
190,884
198,533
208,357
214,319
231,051
238,228
263,966
276,711
308,951
359,051
403,430
403,430
Sales/Revenue/Turnover
1.81
1.86
1.91
1.82
1.74
1.91
1.75
1.4
1.55
1.23
1.38
0.98
1.66
1.35
1.34
1.6
1.6
Operating Margin (%)
496
493
581
735
1,017
885
910
951
949
922
887
760
608
635
636
729
729
Depreciation Expense
1,202
1,403
1,338
1,263
1,476
2,258
5,070
67
34
900
-4,539
1,114
3,560
3,002
3,295
4,762
4,762
Net Income, GAAP
30.89
27.15
30.1
34.87
30.67
27.94
23.42
- -
58.36
1.57
- -
32.99
19.55
16.6
20.14
17.77
17.77
Effective Tax Rate (%)
1.07
1.15
1.09
0.92
0.82
1.18
2.55
0.03
0.02
0.39
-1.91
0.42
1.29
0.97
0.92
1.18
1.18
Profit Margin (%)
3,631
1,917
1,813
3,221
3,173
3,366
1,336
451
839
-402
1,279
-2,235
-3,665
-4,387
-6,206
-9,807
-9,807
Working Capital
3,587
3,072
4,521
8,929
8,180
6,497
7,305
6,751
7,265
7,995
8,273
6,446
6,028
7,045
5,941
7,060
7,060
LT Debt
7,220
6,831
7,070
10,318
9,471
10,414
12,600
11,516
9,680
6,711
1,446
-1,792
-1,490
-1,599
-1,694
-834
-834
Total Equity
12.19
13.77
12.89
9.05
9.91
13.24
13.45
- -
7.53
16.75
- -
20.93
63.81
60
66.96
78.76
78.76
Return on Invested Capital (%)
12.44
12.34
10.49
7.48
6.97
11.72
25.35
- -
-0.35
4.05
- -
5.87
19.44
14.3
13.71
15.98
15.98
Return on Capital (%)
15.52
15.85
13.47
11.55
12.22
21.43
47.04
0.51
0.27
7.08
-42.76
12.93
33.38
22.01
20.03
23.68
23.68
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
2,025
1,418
1,554
LT Borrowings
6,011
5,425
5,259
LT Finance Leases
1,756
1,781
1,801
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
124
123
120
Market Capitalization
96,587
101,983
106,915

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
59,887
59,697
57,210
Cash, Cash Equivalents & STI
4,004
2,959
3,975
Accounts Receivable, Net
28,286
28,213
24,247
Inventories
26,134
27,067
24,207
Total Current Liabilities
68,031
68,131
67,017
Payables & Accruals
66,006
66,713
65,463
ST Debt
2,025
1,418
1,554
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-39.1%
-55.66%
-50.77%
Free Cash Flow
8.31%
9.79%
3.08%
Net Income, GAAP
205.3%
26.73%
44.52%
Sales/Revenue/Turnover
7.86%
11.17%
12.36%
Total Cash Common Dividend
4.69%
6.72%
10.43%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
74,483
77,215
80,898
76,355
308,951
2025
79,283
93,651
95,294
90,823
359,051
2026
97,827
103,150
106,158
96,295
403,430

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7.07
4.95
4.45
6.05
22.54
2025
7.05
1.87
6.98
10.06
25.86
2026
6.28
8.95
9.63
13.78
38.53

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.55
0.56
0.63
0.63
2.36
2025
0.63
0.62
0.73
0.73
2.71
2026
0.72
0.72
0.82
0.83
3.08
Similar Companies
ClouDr Group Limited (9955.HK)
Saintmed Public Company Limited (SMD.BK)
DH Enchantment Inc. (ENMI)
MedFirst Healthcare Services, Inc. (4175.TWO)
China Tian Yuan Healthcare Group Limited (0557.HK)
Galenica AG (GALE.SW)
Business
McKesson Corporation (NYSE: MCK) operates as a diversified healthcare services company, primarily engaged in pharmaceutical distribution, medical-surgical supply distribution, oncology and multispecialty solutions, and prescription technology services. The company distributes pharmaceuticals and medical supplies through its North American Pharmaceutical segment, which serves retail and community pharmacies, specialty care settings, and health systems across the United States and Canada via a network of distribution centers; its Oncology and Multispecialty segment provides practice management, technology solutions, specialty drug distribution, clinical trial services, group purchasing, and pharmacy solutions for community-based oncology practices and providers in retina and ophthalmology; its Medical-Surgical Solutions segment merchandises and distributes more than 285,000 national brand products alongside McKesson's own brands of medical-surgical supplies, pharmaceuticals, laboratory equipment, and supplies to physician offices, surgery centers, long-term care providers, home health agencies, health systems, government facilities, and online retailers in the United States; and its Prescription Technology Solutions segment offers medication access, affordability, and adherence programs, including prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support connecting patients, pharmacies, providers, payers, and biopharma companies. [fetch:https://www.mckesson.com/about-us/business-segments/] Founded in 1833 and headquartered in Irving, Texas, McKesson serves healthcare providers, pharmacies, biopharma manufacturers, governments, and consumers primarily in North America, with additional distribution and retail operations in Norway, which it agreed to sell in August 2025. [fetch:https://www.mckesson.com/about-us/history/] In recent strategic developments, McKesson acquired a controlling interest in Community Oncology Revitalization Enterprise Ventures (Core Ventures), associated with Florida Cancer Specialists & Research Institute, for $2.49 billion in August 2024 to bolster oncology care; welcomed Florida Cancer Specialists as a member of The US Oncology Network; acquired a controlling interest in PRISM Vision Group to expand into ophthalmology and retina care; formed a joint venture between US Oncology Research and HCA Healthcare's Sarah Cannon Research Institute to advance oncology research and clinical trials; and announced in September 2025 a corporate restructuring into four segments—North American Pharmaceutical, Oncology and Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions—effective fiscal 2026, alongside plans to separate the Medical-Surgical Solutions segment and updated long-term growth targets including 13% to 16% adjusted earnings per share growth. [fetch:https://www.mckesson.com/about-us/history/]

Company News

APIChatGPT

  • defenseworld.net

    Dimensional Fund Advisors LP Raises Stock Position in McKesson Corporation $MCK

  • zacks.com

    Here's Why McKesson (MCK) Fell More Than Broader Market

  • zacks.com

    Is Trending Stock McKesson Corporation (MCK) a Buy Now?

  • businesswire.com

    McKesson Corporation Raises Quarterly Dividend by 15% to $0.94 Per Share

  • zacks.com

    Here's Why McKesson (MCK) is a Strong Growth Stock

  • zacks.com

    McKesson (MCK) Declines More Than Market: Some Information for Investors

  • zacks.com

    Here's Why McKesson (MCK) is a Strong Value Stock

  • zacks.com

    McKesson (MCK) Stock Dips While Market Gains: Key Facts

  • zacks.com

    Zacks Industry Outlook McKesson, Cardinal, West Pharmaceutical, Align and Henry

  • zacks.com

    5 Medical Supply Stocks to Buy Amid Strong Industry Tailwinds

  • zacks.com

    Brokers Suggest Investing in McKesson (MCK): Read This Before Placing a Bet

  • zacks.com

    McKesson Corporation (MCK) is Attracting Investor Attention: Here is What You Should Know

  • zacks.com

    McKesson (MCK) Increases Despite Market Slip: Here's What You Need to Know

  • zacks.com

    Will McKesson (MCK) Beat Estimates Again in Its Next Earnings Report?

  • fool.com

    Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

  • seekingalpha.com

    McKesson: The Healthcare Supplier On My Buy List This Summer, As Growth Accelerates

  • zacks.com

    Here's Why You Should Retain McKesson Stock in Your Portfolio for Now

  • zacks.com

    Here's Why McKesson (MCK) is a Strong Growth Stock

  • zacks.com

    Here's Why McKesson (MCK) is a Strong Momentum Stock

  • zacks.com

    McKesson (MCK) Stock Falls Amid Market Uptick: What Investors Need to Know